Evidence map›Paper›PMID 37060320›Full record

ArticleJournal of chemical information and modeling2023

Scaffold Hopping and Optimization of Small Molecule Soluble Adenyl Cyclase Inhibitors Led by Free Energy Perturbation.

Shan Sun, Makoto Fushimi, Thomas Rossetti, Navpreet Kaur, Jacob Ferreira, Michael Miller, Jonathan Quast, Joop van den Heuvel, Clemens Steegborn, Lonny R Levin and 6 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Journal of chemical information and modeling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Scaffold Hopping with Generative Reinforcement Learning.Journal of chemical information and modeling · 2025
    Article
  2. Article
  3. Biochemistry research international · 2025
    Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Shan SunTri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.
Makoto FushimiTri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.
Thomas RossettiDepartment of Pharmacology, Weill Cornell Medicine, New York City, New York 10056, United States.
Navpreet KaurDepartment of Pharmacology, Weill Cornell Medicine, New York City, New York 10056, United States.
Jacob FerreiraDepartment of Pharmacology, Weill Cornell Medicine, New York City, New York 10056, United States.
Michael MillerTri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.
Jonathan QuastDepartment of Biochemistry, University of Bayreuth, Bayreuth 95440, Germany.
Joop van den HeuvelHelmholtz-Zentrum für Infektionsforschung, Braunschweig 38124, Germany.
Clemens SteegbornDepartment of Biochemistry, University of Bayreuth, Bayreuth 95440, Germany.ORCID 0000-0002-0913-1467
Lonny R LevinDepartment of Pharmacology, Weill Cornell Medicine, New York City, New York 10056, United States.ORCID 0000-0002-5204-6356
Jochen BuckDepartment of Pharmacology, Weill Cornell Medicine, New York City, New York 10056, United States.
Robert W MyersTri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.ORCID 0000-0003-2599-1050
Stacia KargmanTri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.
Nigel LivertonTri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.
Peter T MeinkeTri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.ORCID 0000-0002-7548-6215
David J HugginsTri-Institutional Therapeutics Discovery Institute, New York, New York 10021, United States.ORCID 0000-0003-1579-2496
Cornell University · USTri-Institutional Therapeutics Discovery Institute · USUniversity of Bayreuth · DEHelmholtz Centre for Infection Research · DE

Funding

Crosstalk between metabolic and signaling pathways involved in sperm capacitationR01HD088571 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI JOCHEN BUCK, LONNY R LEVIN · 2017 to 2026
$6.1M
Optimization and pre-clinical evaluation of ADCY10 inhibitorsP50HD100549 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI BUCK, JOCHEN, LEVIN, LONNY R · 2019 to 2021
$6.0M
Discovery and Characterization of an Endogenous Inhibitor of Soluble Adenylyl CyclaseF31HD105363 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI FERREIRA, JACOB · 2021 to 2023
$140k
Activation of Soluble Adenylyl Cyclase as a Novel Therapeutic Strategy for the Treatment of Age-Related Neurodegenerative DisordersF31AG069501 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROSSETTI, THOMAS · 2020 to 2022
$129k
NIA NIH HHS F31 AG069501NICHD NIH HHS F31 HD105363NICHD NIH HHS P50 HD100549NICHD NIH HHS R01 HD088571
6 · The paper itself

Abstract

Free energy perturbation is a computational technique that can be used to predict how small changes to an inhibitor structure will affect the binding free energy to its target. In this paper, we describe the utility of free energy perturbation with FEP+ in the hit-to-lead stage of a drug discovery project targeting soluble adenyl cyclase. The project was structurally enabled by X-ray crystallography throughout. We employed free energy perturbation to first scaffold hop to a preferable chemotype and then optimize the binding affinity to sub-nanomolar levels while retaining druglike properties. The results illustrate that effective use of free energy perturbation can enable a drug discovery campaign to progress rapidly from hit to lead, facilitating proof-of-concept studies that enable target validation.

Indexed as

Adenylyl CyclasesDrug DiscoveryEntropyThermodynamicsAdenylyl Cyclases

Identifiers

PMID37060320
PMCPMC12463311
OpenAlexW4365810972

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.